Pharm-Olam International Appoints Industry Veteran Dr. Kelly McKee as Chief Medical Officer; Enhances Infectious Disease & Vaccine Competencies
HOUSTON, TEXAS (PRWEB) January 11, 2018 -- Pharm-Olam International, a multinational, full-service Clinical Research Organization (CRO) specializing in Oncology, Infectious Diseases, Rare Diseases and Pediatric indications, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H. as Chief Medical Officer (CMO).
“Dr. McKee’s addition to our team represents a strategic investment in Pharm-Olam’s Medical offering, especially to our Infectious Diseases and Vaccines clinical research portfolios,” said David L. Grange, CEO, Pharm-Olam International. “Kelly brings the best of both worlds when it comes to Executive Leadership in a Contract Research Organization and the discipline of medicine.”
Dr. McKee comes to Pharm-Olam from IQVIA (previously QuintilesIMS), where he recently served as Vice President, Vaccines and Public Health, in the Infectious Diseases and Vaccines Center of Excellence. He brings over 30 years of experience in research and development from the bench to the bedside, with specific expertise in vaccines, emerging diseases, biodefense, respiratory viral infections, and sexually transmitted infections. His progressive clinical research experience began in 1981 at Fort Detrick, Frederick, Md., United States, where he served as a research virologist and immunologist in the U.S. Army.
“Infectious Disease and Vaccine research and development is my passion, and I am excited to be joining the visionary team assembled here at Pharm-Olam,” said Dr. McKee. “I look forward to engaging with our sponsors to assist in navigating their development journeys, and joining in Pharm-Olam’s mission of helping create a healthier world.”
Over the course of a successful military- and private-sector career, Dr. McKee has also earned multiple board and advisory appointments, certifications, grants, civilian honors, and inductions and fellowships to some of the world’s most prestigious medical associations. He has authored, co-authored or peer-reviewed more than 100 publications.
“Dr. McKee’s experience really speaks for itself,” Grange added. “We’re excited to leverage the wealth of knowledge, expertise, and insights he brings to the table.”
Dr. McKee holds an M.D. from the University of Virginia School of Medicine, and a Master of Public Health from Johns Hopkins University School of Hygiene and Public Health in Baltimore, Md.
Pharm-Olam operates in more than 60 countries worldwide, offering end-to-end clinical trial support for Phase I-IV clinical trials. More information about Pharm-Olam and its full-service capabilities and offerings are available at http://www.Pharm-Olam.com, or by request via email [email protected].
About Pharm-Olam International Group
Pharm-Olam International is a multinational Contract Research Organization (CRO) offering comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines, making clinical research as Easy As I, II, III, IV™. For further information about Pharm-Olam, please visit http://www.pharm-olam.com.
John Colby, Executive Vice President, Global Marketing & Communications, Pharm-Olam International, http://www.pharm-olam.com, +1 703-627-7649, [email protected]
Share this article